Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025

mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma

Novo Nordisk to acquire Akero Therapeutics for $5.2 billion

Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases

Allergan Aesthetics launches SkinMedica’s reimagined packaging

SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants

Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis

Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis

WHO and OneSight EssilorLuxottica partner to expand vision care in Karnataka

WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030

VectorBuilder Redefines Plasmid Standards with miniVec

Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively

Lupin to build $250 million manufacturing facility in Florida

Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?

IMCD unveils future of beauty at In-Cosmetics Latin America 2025

IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends

FDA supports new ANDA prioritization pilot to support US generic drugs